Gennex Laboratories receives CGMP from Drugs Control Administration, Telangana

Image
Capital Market
Last Updated : May 22 2017 | 8:28 PM IST

Secures Drug License to launch new product Flupentixol Hydrochloride

Gennex Laboratories announced that it has been awarded by the Drugs Control Administration, Government of Telangana, Certificate for good manufacturing practices in the manufacturing and quality control operations as recommended by the World Health Organization, for a period of 2 years.

This certificate has been awarded after inspection of the Company's manufacturing facility by the Joint Inspection Team of officers from Central Drugs Standard Control Organization and Drugs Control Administration, Telangana with regard to the Company's adherence to manufacturing and quality control norms of World Health Organization. This Award, the Company believes, will provide a cutting-edge to penetrate European market in future.

The Company has also received Consent For Operations (CFO) from the Telangana State Pollution Control Board (TSPCB) for a further period of 5 years after a team of officers who inspected the Company's manufacturing and effluent treatment facilities recorded its satisfaction. The Company, however, continues to make efforts to ensure that the Pollution Control norms are strictly adhered to and necessary measures taken from time to time.

The Drugs Control Administration, Telangana had, on 06 May 2017, approved the Company's new product namely Flupentixol Hydrochloride and issued the Drug Licence for the same. The new product is an anti-depressant drug that goes in combination with Melitracin hydrochloride and is widely in demand notably in countries like Bangladesh

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 22 2017 | 8:02 PM IST

Next Story